In both hepatocellular carcinoma and ovarian cancer, treatment with cisplatin leads to ADAM17-dependent release of cleaved growth factors and subsequent activation of the EGFR/PI3K/AKT pathway. The gene discussed is EGFR; the disease is ovarian carcinoma.